Royal Bank of Canada’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.28M | Buy |
27,283
+22,643
| +488% | +$5.29M | ﹤0.01% | 2316 |
|
|
2026
Q1 | $1.06M | Buy |
4,640
+2,106
| +83% | +$472K | ﹤0.01% | 3578 |
|
|
2025
Q4 | $541K | Sell |
2,534
-4,654
| -65% | -$961K | ﹤0.01% | 4099 |
|
|
2025
Q3 | $1.43M | Buy |
7,188
+5,465
| +317% | +$1.02M | ﹤0.01% | 3687 |
|
|
2025
Q2 | $297K | Sell |
1,723
-30,413
| -95% | -$4.95M | ﹤0.01% | 4866 |
|
|
2025
Q1 | $5.01M | Sell |
32,136
-208
| -0.6% | -$29.7K | ﹤0.01% | 2257 |
|
|
2024
Q4 | $4.45M | Buy |
32,344
+30,617
| +1,773% | +$4.03M | ﹤0.01% | 2410 |
|
|
2024
Q3 | $258K | Sell |
1,727
-5,718
| -77% | -$772K | ﹤0.01% | 4612 |
|
|
2024
Q2 | $1.02M | Buy |
7,445
+298
| +4% | +$40.5K | ﹤0.01% | 3448 |
|
|
2024
Q1 | $1.08M | Sell |
7,147
-288
| -4% | -$41.1K | ﹤0.01% | 3400 |
|
|
2023
Q4 | $936K | Buy |
7,435
+572
| +8% | +$57K | ﹤0.01% | 3719 |
|
|
2023
Q3 | $642K | Sell |
6,863
-3,150
| -31% | -$295K | ﹤0.01% | 3822 |
|
|
2023
Q2 | $894K | Buy |
10,013
+9,013
| +901% | +$784K | ﹤0.01% | 3457 |
|
|
2023
Q1 | $107K | Sell |
1,000
-66
| -6% | -$7.55K | ﹤0.01% | 5127 |
|
|
2022
Q4 | $131K | Sell |
1,066
-437
| -29% | -$50.7K | ﹤0.01% | 5252 |
|
|
2022
Q3 | $155K | Sell |
1,503
-971
| -39% | -$92.1K | ﹤0.01% | 4970 |
|
|
2022
Q2 | $230K | Buy |
2,474
+85
| +4% | +$8.01K | ﹤0.01% | 4696 |
|
|
2022
Q1 | $281K | Buy |
2,389
+732
| +44% | +$84.8K | ﹤0.01% | 4779 |
|
|
2021
Q4 | $223K | Sell |
1,657
-509
| -23% | -$75.7K | ﹤0.01% | 5230 |
|
|
2021
Q3 | $345K | Buy |
2,166
+310
| +17% | +$42.4K | ﹤0.01% | 4663 |
|
|
2021
Q2 | $244K | Buy |
1,856
+69
| +4% | +$9.19K | ﹤0.01% | 4904 |
|
|
2021
Q1 | $231K | Buy |
1,787
+227
| +15% | +$34.5K | ﹤0.01% | 4827 |
|
|
2020
Q4 | $260K | Buy |
1,560
+277
| +22% | +$45.8K | ﹤0.01% | 4664 |
|
|
2020
Q3 | $198K | Buy |
1,283
+59
| +5% | +$8.48K | ﹤0.01% | 4556 |
|
|
2020
Q2 | $181K | Buy |
1,224
+324
| +36% | +$44.5K | ﹤0.01% | 4520 |
|
|
2020
Q1 | $101K | Hold |
900
| – | – | ﹤0.01% | 4768 |
|
|
2019
Q4 | $125K | Sell |
900
-15
| -2% | -$1.67K | ﹤0.01% | 4959 |
|
|
2019
Q3 | $88K | Hold |
915
| – | – | ﹤0.01% | 4859 |
|
|
2019
Q2 | $106K | Buy |
915
+15
| +2% | +$1.79K | ﹤0.01% | 4834 |
|
|
2019
Q1 | $106K | Sell |
900
-100
| -10% | -$8.76K | ﹤0.01% | 4741 |
|
|
2018
Q4 | $63K | Hold |
1,000
| – | – | ﹤0.01% | 4969 |
|
|
2018
Q3 | $71K | Buy |
1,000
+997
| +33,233% | +$68.6K | ﹤0.01% | 5053 |
|
|
2018
Q2 | $0 | Sell |
3
-1
| -25% | -$66 | ﹤0.01% | 6496 |
|
|
2018
Q1 | $0 | Sell |
4
-15
| -79% | -$843 | ﹤0.01% | 6321 |
|
|
2017
Q4 | $1K | Buy |
+19
| New | +$691 | ﹤0.01% | 6360 |
|
|
2016
Q1 | – | Sell |
-6
| Closed | – | – | 6333 |
|
|
2015
Q4 | $0 | Sell |
6
-36
| -86% | -$631 | ﹤0.01% | 6617 |
|
|
2015
Q3 | $1K | Sell |
42
-141
| -77% | -$2.75K | ﹤0.01% | 6458 |
|
|
2015
Q2 | $3K | Buy |
+183
| New | +$3.2K | ﹤0.01% | 6308 |
|
Other funds holding ASND
RCM
ACA
JT
Royal Bank of Canada's ASND Position: Q2 2026 in Review
Royal Bank of Canada increased its Ascendis Pharma A/S (ASND) stake by 488% in Q2 2026, buying an estimated $5.29M and bringing the position to 27,283 shares worth $7.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2316.
Royal Bank of Canada first reported a position in ASND in Q2 2015 and has held it in 38 quarters since. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- Royal Bank of Canada held 27,283 shares of Ascendis Pharma A/S worth $7.28M as of Q2 2026.
- Royal Bank of Canada bought 22,643 Ascendis Pharma A/S shares in Q2 2026, an estimated $5.29M.
- Ascendis Pharma A/S made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #2316 holding.
- Royal Bank of Canada first reported a position in Ascendis Pharma A/S in Q2 2015 and has held it in 38 quarters since.
- 311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.